Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

There has been a rapid emergence of numerous targeted agents in the oncology community
in the last decade. This exciting paradigm shift in drug development lends promise for the …

Neutrophilic dermatoses are a heterogeneous group of inflammatory skin disorders that
present with unique clinical features but are unified by the presence of a sterile …

Imatinib mesylate is the first of a novel group of drugs that specifically target protein tyrosine
kinases, which are central to the pathogenesis of human cancer. It has been approved for …

The identification of oncogenic drivers of liquid tumors has led to the rapid development of
targeted agents with distinct cutaneous adverse event (AE) profiles. The diagnosis and …

In the last years, several tyrosine kinase inhibitors (TKIs) have been developed and
approved for human cancer treatment. Imatinib mesylate was the first of this novel family of …

Drug reactions resulting from chemotherapy agents are common and frequently affect the
skin. Although often benign, a select few of these cutaneous reactions may necessitate …

Background: Recently developed tyrosine kinase inhibitors (TKIs) offer first-line alternatives
to patients with chronic myeloid leukemia. While these medications are generally well …

Targeted cancer treatments—designed to interfere with specific molecular signals
responsible for tumor survival and progression—have shown benefit over conventional …

Tyrosine kinase inhibitors are a class of targeted anticancer drugs that inhibit cancer cell
proliferation by inactivating proteins involved in signal transduction cascades. Various …